All In Biotech

Free tool

FAERS Monitor: Livmarli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214662 or its brand name (Livmarli, Maralixibat Chloride). Reports on generic versions are filed under their own applications.

Reports

1,002

Serious

284

28% of reports

Hospitalization

158

Death reported

21

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus258
  • off label use120
  • liver transplant103
  • diarrhoea101
  • drug ineffective83
  • hepatic enzyme increased78
  • alanine aminotransferase increased67
  • blood bilirubin increased64
  • aspartate aminotransferase increased59
  • bile acids increased53
  • jaundice44
  • vomiting41
  • product dose omission issue36
  • nasopharyngitis34
  • abdominal pain32

Reports by year received

View as table
YearReports
20212
2022336
2023199
2024147
2025163
2026155

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bile acids increasedSignal538980.66549.7327,115
liver transplantSignal103612.0508.260,473
blood bilirubin increasedSignal6449.939.33,012
jaundiceSignal4434.425.81,393
hepatic enzyme increasedSignal7824.019.41,703
aspartate aminotransferase increasedSignal5923.318.21,241
alanine aminotransferase increasedSignal6722.918.21,386
pruritusSignal25814.112.73,183
nasopharyngitisSignal343.92.870
diarrhoeaSignal1013.32.7163
abdominal painSignal322.92.138
off label useSignal1202.92.4151
product dose omission issueSignal362.61.933
vomiting411.81.415
drug ineffective831.31.17

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.